Hui Xiao

Dr. Hui Xiao


Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
GWGuoqiang Wang
Guoqiang Wang
XYXuan Ye
Xuan Ye
TLTing Lu
Ting Lu
YYYunxi Yang
Yunxi Yang
BSBingwei Sun
Bingwei Sun
HXHui Xiao
Hui Xiao
Hashimoto’s Thyroiditis (HT) is an autoimmune disorder characterized by metabolic disturbances. However, a comprehensive metabolic and lipid profile of HT has not been reported. The metabolic and lipid profile of HT can be comprehensively analyzed through metabolomics and lipidomics technologies, providing a detailed understanding of the disease’s biochemical alterations. Plasma samples were obtained from 20 mice, comprising 10 from the control group and 10 from the HT group. Plasma metabolomics and lipidomics were analyzed via LC-MS/MS. PCA, PLS-DA, and OPLS-DA of the preprocessed data matrix were conducted using the ropls package (V.1.6.2) in R. The identification of significant differential metabolites was based on the VIP scores in the OPLS-DA model and p-values (Student’s t-test). Metabolites (VIP exceeding 1 and p < 0.05) were classified as significantly different. Pathway annotation of these metabolites was carried out using the KEGG database to identify associated metabolic pathways. Pathway enrichment analysis was performed using the Python scipy. Stats package, with Fisher’s exact test employed to identify biological pathways most relevant to the experimental conditions. Metabolomics identified 6384 metabolites (2943 in positive ion mode and 3441 in negative), with 195 differential metabolites, comprising 114 upregulated and 81 downregulated in the HT group. Lipidomics analysis revealed 1054 lipid metabolites (695 detected in positive ion mode and 359 in negative), and 247 differentially expressed lipids were identified, including 165 upregulated and 82 downregulated in the HT group. KEGG enrichment analysis indicated that metabolites upregulated in the HT group were primarily associated with pathways such as Autophagy, Choline metabolism, PPAR signaling, and Glycerophospholipid metabolism. In contrast, pathways involved in Apoptosis, Cholesterol metabolism, Sphingolipid metabolism, EGFR tyrosine kinase inhibitor resistance, Th1 and Th2 cell differentiation, viral infection, and Chemokine signaling were suppressed. Metabolic and lipidomic dysregulation was observed in HT animal models, with pronounced alterations in Phospholipids, Eicosanoids, and Carnitines. Choline, Glycerophospholipid, and Linoleic acid metabolism pathways exhibited significant enrichment in HT.

29 November 2024 in Medicine
Verified
Journal Article
Open access
GWGuoqiang Wang
Guoqiang Wang
HXHui Xiao
Hui Xiao
ZLZhipan Liang
Zhipan Liang
YFYuxin Feng
Yuxin Feng
LWLiyu Wang
Liyu Wang
LZLuyao Zhang
Luyao Zhang
The tyrosine kinase ephrin type-A receptor 2 (EPHA2) was remarkably elevated expressed in various tumors and plays a crucial role in cancer tumorigenesis and progression, while pan-cancer analyses are currently lacking. This study was designed to analyze the expression status and prognostic significance of EPHA2 in pan-cancer. By mining The Cancer Genome Atlas data, we performed a comprehensive and systematic characterization of EPHA2 across >10,000 samples of 33 types of cancer. EPHA2 expressions were substantially different in most of the normal control and tumor tissues, and it was considerably associated with the prognosis of tumor patients. EPHA2 gene modifications in malignant tumors were mainly missense mutations. There was a significant correlation between EPHA2 expression and cancer-associated fibroblasts in most The Cancer Genome Atlas cancers. Furthermore, functional enrichment analysis showed that the biological role of EPHA2 in tumors was mainly involved in some noticeably pro-oncogenic pathways, such as the Ras signaling pathway, PI3K-Akt signaling pathway, ErbB signaling pathway, MAPK signaling pathway, etc. This study provided the first pan-cancer analyses of EPHA2 in various tumors, and EPHA2 was potentially involved in many cancer types and can be developed as candidates for cancer diagnosis, prognosis, and therapeutic biomarkers. In addition, EPHA2 seemed to be a key modulator of the tumor immune microenvironment and might be a potential biomarker in predicting the immunotherapeutic efficacy for cancer patients.